Rognvaldsson, Saemundur http://orcid.org/0000-0003-2162-8414
Eythorsson, Elias
Thorsteinsdottir, Sigrun http://orcid.org/0000-0001-5017-3530
Vidarsson, Brynjar
Onundarson, Pall Torfi
Agnarsson, Bjarni A.
Sigurdardottir, Margret
Thorsteinsdóttir, Ingunn
Olafsson, Isleifur
Runolfsdottir, Hrafnhildur L. http://orcid.org/0000-0003-1826-1383
Helgason, Dadi
Emilsdottir, Arna R. http://orcid.org/0000-0003-2300-8702
Agustsson, Arnar S.
Bjornsson, Aron H. http://orcid.org/0000-0002-2595-7015
Kristjansdottir, Gudrun
Thordardottir, Asdis Rosa
Indridason, Olafur Skuli
Jonsson, Asbjorn http://orcid.org/0000-0001-8509-6598
Gislason, Gauti Kjartan http://orcid.org/0000-0003-4710-0781
Olafsson, Andri
Steingrimsdottir, Hlif
Kampanis, Petros
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Durie, Brian G. M.
Harding, Stephen
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Palsson, Runolfur
Love, Thorvarður Jon
Kristinsson, Sigurdur Yngvi http://orcid.org/0000-0002-4964-7476
Article History
Received: 3 September 2021
Revised: 1 November 2021
Accepted: 11 November 2021
First Online: 1 December 2021
Competing interests
: P.K. is an employee of The Binding Site. M.H. has received research funding from Amgen and Daiichi Sankyo, has provided consultancy for Intellisphere LLC and Curio Science LLC, and served on an advisory committee for GlaxoSmithKline. B.G.M.D. has provided consultancy for Amgen, Janssen, Celgene, Takeda. S.H. is the director of The Binding Site. O.L. has received research funding from National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; and received honorariacompensation for advisory boards from Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. S.Y.K. has received research funding from International Myeloma Foundation, European Research Council, Icelandic Center for Research (Rannís), Amgen, Celgene. Other coauthors have nothing to disclose.